Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative hypofractionated low-dose radiotherapy plus PD-1 inhibitor in stage III gastric cancer
ChiCTR2000034965Phase 2Not yet recruiting
- Sponsor
- Changzhou Second People's Hospital
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of tislelizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Changzhou Second People's Hospital. Primary endpoints: Disease-free survival (DFS), Circulating tumor DNA (ct-DNA) and 4 more. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2000034965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034965.